Targeted missile drug tested against tough cancers

NCT ID NCT04659603

Summary

This study tested an experimental drug, tusamitamab ravtansine, in people with advanced breast or pancreatic cancer that had spread. The drug is designed to target and deliver chemotherapy directly to cancer cells that have a specific marker called CEACAM5. The trial aimed to see if the drug, given alone or with standard chemotherapy, could shrink tumors and was safe for patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AdventHealth Orlando Site Number : 8400001

    Orlando, Florida, 32804, United States

  • Investigational Site Number : 0320001

    Pergamino, Buenos Aires, B2700CPM, Argentina

  • Investigational Site Number : 0320002

    Rosario, Santa Fe Province, 2000, Argentina

  • Investigational Site Number : 0320003

    Capital Federal, Buenos Aires, 1012, Argentina

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, 8420383, Chile

  • Investigational Site Number : 1520002

    Temuco, La Araucanía, 4800827, Chile

  • Investigational Site Number : 1520003

    Santiago, Reg Metropolitana de Santiago, 7500921, Chile

  • Investigational Site Number : 1580001

    Taichung, 40447, Taiwan

  • Investigational Site Number : 1580002

    Tainan, 704, Taiwan

  • Investigational Site Number : 1580003

    Taipei, 11217, Taiwan

  • Investigational Site Number : 3480003

    Budapest, 1122, Hungary

  • Investigational Site Number : 4100001

    Seoul, Seoul-teukbyeolsi, 03080, South Korea

  • Investigational Site Number : 4100002

    Seoul, Seoul-teukbyeolsi, 06351, South Korea

  • Investigational Site Number : 4100003

    Goyang-si, Gyeonggi-do, 10408, South Korea

  • Investigational Site Number : 5280001

    Rotterdam, 3015 GD, Netherlands

  • Investigational Site Number : 5280002

    Amsterdam, 1066 CX, Netherlands

  • Investigational Site Number : 5280003

    Utrecht, 3584 CX, Netherlands

  • Investigational Site Number : 6430001

    Moscow, 115478, Russia

  • Investigational Site Number : 6430002

    Saint Petersburg, 197758, Russia

  • Investigational Site Number : 6430004

    Pushkin, Saint- Petersburg, 196603, Russia

  • Investigational Site Number : 7240001

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Investigational Site Number : 7240002

    Majadahonda, Madrid, 28222, Spain

  • Investigational Site Number : 7240003

    Madrid, Madrid, Comunidad de, 28046, Spain

  • Investigational Site Number : 7920001

    Istanbul, 34722, Turkey (Türkiye)

  • Investigational Site Number : 7920002

    Izmir, Turkey (Türkiye)

  • Investigational Site Number : 7920003

    Adana, 01250, Turkey (Türkiye)

  • Investigational Site Number : 7920004

    Ankara, 06100, Turkey (Türkiye)

  • Massachusetts General Hospital Site Number : 8400002

    Boston, Massachusetts, 02114, United States

  • University of Wisconsin Site Number : 8400004

    Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.